Management of Primary Hepatopancreatobiliary and Ampulla Large Cell Neuroendocrine Carcinoma

• DOI: 10.1089/lap.2021.0482
• Publication Date: 2021-10-12T22:51:47Z
• Authors: Jisheng Zhu; Weidong Xiao; Yong Li
• Keywords: Ampulla of Vater; Adjuvant Therapy; Primary tumor

Background: Large cell neuroendocrine carcinoma (LCNEC) of the liver, gallbladder, pancreas, and ampulla is rare usually arises in case reports, thus to date, no studies have well described treatment options outcomes those patients. Methods: The data 108 patients diagnosed as hepatopancreatobiliary LCNEC between 2004 2015 were retrieved from surveillance, epidemiology, final results. Results: In entire cohort, median overall survival (OS) was 10 months. For nonmetastatic patients, OS 32 months for surgery primary tumor alone (n = 17), 19 adjuvant therapy 19), 1 month nonsurgical 8). metastatic 14 who received with without 16), 9 undergoing 30), had 16). Multivariate analysis revealed that an independent factor improved survival. Conclusions: This disease offers a very poor prognosis despite aggressive treatment. Radical resection first choice resectable tumors, whereas surgical plus might represent valid option disease. However, further are needed confirm this.